Dr. Delaughter specializes in Electrophysiology and Cardiovascular Disease.
Dr. Lander specializes in Interventional Cardiology and Cardiovascular Disease.
Dr. Vignale specializes in Interventional Cardiology and Cardiovascular Disease.
Dr. Patel specializes in Cardiovascular Disease.
HeartPlace is the past, present, and future of cardiology in North Texas. Founded almost 50 years ago, HeartPlace is the oldest and largest cardiovascular group in North Texas. From its small beginning in Dallas, HeartPlace has grown to over 70 physicians throughout the Dallas-Fort Worth metroplex. HeartPlace has been an innovator in cardiovascular services, introducing to the North Texas area procedures such as coronary angiography, angioplasty, coronary stenting, and electrophysiology. This dedication to innovative techniques and procedures has guaranteed our patients the latest and most up-to-date cardiovascular services...
Laser ablation for varicose veins is an effective and minimally invasive technique for the treatment of varicose. However, this kind of therapy is associated with significant collateral damage because of the high output power of the laser. Therefore, it is an important issue in vein surgery to optimize the laser characteristics for ablation.
Endovascular treatment (EVT) of intracranial aneurysm is effective in preventing long-term bleeding, but may be followed by aneurysm recurrences in a significant proportion of cases, according to a new magnetic resonance angiography (MRA) study published online in the journal Radiology. Source: Medical News Today Read More Read More
Never forget another appointment! We are now offering text and email* appointment reminders. We have 3 convenient ways to opt in, please see the front desk staff, text HEARTPLACE to 622622, or scan the QR code on this flyer. Read More Read More
There have been tremendous advances in the catheter-based treatment of stroke, in particular the use of stent retrievers and, more recently, even embolectomy catheters, which have greatly improved functional outcomes in patients presenting with acute ischemic stroke.
Source:Healio Read More
For treating patients with chronic heart failure, ACE inhibitors are usually the first port of call. But a new study claims an experimental drug called LCZ696 performs around 20% better than ACE inhibitors when it comes to reducing rates of hospitalizations and deaths due to chronic heart failure. Source: MedicalNewsToday Read More Read More